IBDEI20T ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,33859,0)
 ;;=E87.70^^154^1708^10
 ;;^UTILITY(U,$J,358.3,33859,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33859,1,3,0)
 ;;=3^Fluid Overload,Unspec
 ;;^UTILITY(U,$J,358.3,33859,1,4,0)
 ;;=4^E87.70
 ;;^UTILITY(U,$J,358.3,33859,2)
 ;;=^5003023
 ;;^UTILITY(U,$J,358.3,33860,0)
 ;;=E87.5^^154^1708^13
 ;;^UTILITY(U,$J,358.3,33860,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33860,1,3,0)
 ;;=3^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,33860,1,4,0)
 ;;=4^E87.5
 ;;^UTILITY(U,$J,358.3,33860,2)
 ;;=^60041
 ;;^UTILITY(U,$J,358.3,33861,0)
 ;;=E87.6^^154^1708^19
 ;;^UTILITY(U,$J,358.3,33861,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33861,1,3,0)
 ;;=3^Hypokalemia
 ;;^UTILITY(U,$J,358.3,33861,1,4,0)
 ;;=4^E87.6
 ;;^UTILITY(U,$J,358.3,33861,2)
 ;;=^60610
 ;;^UTILITY(U,$J,358.3,33862,0)
 ;;=E87.8^^154^1708^8
 ;;^UTILITY(U,$J,358.3,33862,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33862,1,3,0)
 ;;=3^Electrolyte & Fluid Balance Disorders NEC
 ;;^UTILITY(U,$J,358.3,33862,1,4,0)
 ;;=4^E87.8
 ;;^UTILITY(U,$J,358.3,33862,2)
 ;;=^5003026
 ;;^UTILITY(U,$J,358.3,33863,0)
 ;;=E26.81^^154^1708^5
 ;;^UTILITY(U,$J,358.3,33863,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33863,1,3,0)
 ;;=3^Bartter's Syndrome
 ;;^UTILITY(U,$J,358.3,33863,1,4,0)
 ;;=4^E26.81
 ;;^UTILITY(U,$J,358.3,33863,2)
 ;;=^329906
 ;;^UTILITY(U,$J,358.3,33864,0)
 ;;=E23.2^^154^1708^7
 ;;^UTILITY(U,$J,358.3,33864,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33864,1,3,0)
 ;;=3^Diabetes Insipidus
 ;;^UTILITY(U,$J,358.3,33864,1,4,0)
 ;;=4^E23.2
 ;;^UTILITY(U,$J,358.3,33864,2)
 ;;=^33572
 ;;^UTILITY(U,$J,358.3,33865,0)
 ;;=E83.41^^154^1708^14
 ;;^UTILITY(U,$J,358.3,33865,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33865,1,3,0)
 ;;=3^Hypermagnesemia
 ;;^UTILITY(U,$J,358.3,33865,1,4,0)
 ;;=4^E83.41
 ;;^UTILITY(U,$J,358.3,33865,2)
 ;;=^5003002
 ;;^UTILITY(U,$J,358.3,33866,0)
 ;;=E21.3^^154^1708^16
 ;;^UTILITY(U,$J,358.3,33866,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33866,1,3,0)
 ;;=3^Hyperparathyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,33866,1,4,0)
 ;;=4^E21.3
 ;;^UTILITY(U,$J,358.3,33866,2)
 ;;=^331438
 ;;^UTILITY(U,$J,358.3,33867,0)
 ;;=E83.42^^154^1708^20
 ;;^UTILITY(U,$J,358.3,33867,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33867,1,3,0)
 ;;=3^Hypomagnesemia
 ;;^UTILITY(U,$J,358.3,33867,1,4,0)
 ;;=4^E83.42
 ;;^UTILITY(U,$J,358.3,33867,2)
 ;;=^5003003
 ;;^UTILITY(U,$J,358.3,33868,0)
 ;;=N25.1^^154^1708^24
 ;;^UTILITY(U,$J,358.3,33868,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33868,1,3,0)
 ;;=3^Nephrogenic Diabetes Insipidus
 ;;^UTILITY(U,$J,358.3,33868,1,4,0)
 ;;=4^N25.1
 ;;^UTILITY(U,$J,358.3,33868,2)
 ;;=^5015616
 ;;^UTILITY(U,$J,358.3,33869,0)
 ;;=E27.49^^154^1708^2
 ;;^UTILITY(U,$J,358.3,33869,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33869,1,3,0)
 ;;=3^Adrenocortical Insufficiency,Other
 ;;^UTILITY(U,$J,358.3,33869,1,4,0)
 ;;=4^E27.49
 ;;^UTILITY(U,$J,358.3,33869,2)
 ;;=^5002743
 ;;^UTILITY(U,$J,358.3,33870,0)
 ;;=E72.09^^154^1708^4
 ;;^UTILITY(U,$J,358.3,33870,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33870,1,3,0)
 ;;=3^Amino-Acid Transport Disorders,Other
 ;;^UTILITY(U,$J,358.3,33870,1,4,0)
 ;;=4^E72.09
 ;;^UTILITY(U,$J,358.3,33870,2)
 ;;=^5002895
 ;;^UTILITY(U,$J,358.3,33871,0)
 ;;=N25.89^^154^1708^22
 ;;^UTILITY(U,$J,358.3,33871,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33871,1,3,0)
 ;;=3^Impaired Renal Tubular Function Disorders,Other
 ;;^UTILITY(U,$J,358.3,33871,1,4,0)
 ;;=4^N25.89
 ;;^UTILITY(U,$J,358.3,33871,2)
 ;;=^5015618
 ;;^UTILITY(U,$J,358.3,33872,0)
 ;;=E26.89^^154^1708^11
 ;;^UTILITY(U,$J,358.3,33872,1,0)
 ;;=^358.31IA^4^2
